A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer

Trial Profile

A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Cancer metastases; Colorectal cancer; Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms PERIOP-01
  • Most Recent Events

    • 13 Sep 2016 Planned End Date changed from 1 Aug 2023 to 1 Dec 2024.
    • 13 Sep 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2022.
    • 05 Dec 2013 Planned end date changed from 1 Aug 2020 to 1 Aug 2023 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top